In order to determine the transcriptional signatures of the observed superior cancer immune response associated with genetic Nr2f6 inhibition, alone and particularly in combination with the established PD-1/PD-L1 axis blocking, we next examined the network of critical target genes in CD3+ TILs, employing a stratified CD45+/CD3+ sorting strategy. This evidence concerns the gene NR2F6 and cancer.